Rigel Provides Business Update and 2025 Outlook
Portfolio Pulse from
Rigel Pharmaceuticals reported preliminary Q4 2024 revenue of $57.6 million, with significant contributions from TAVALISSE®, REZLIDHIA®, and GAVRETO®. The company anticipates 2025 revenue between $200 to $210 million. Additionally, R289 received Orphan Drug designation from the FDA.
January 13, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rigel Pharmaceuticals reported strong Q4 2024 revenue and projects significant growth in 2025. The Orphan Drug designation for R289 could enhance future prospects.
The reported Q4 2024 revenue of $57.6 million, driven by key products, indicates strong performance. The 2025 revenue projection of $200-$210 million suggests expected growth. The Orphan Drug designation for R289 by the FDA is a positive regulatory development that could lead to market exclusivity and enhance future revenue potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100